Stephens Consulting LLC Acquires 402 Shares of AstraZeneca PLC (NASDAQ:AZN)

Stephens Consulting LLC increased its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 61.3% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,058 shares of the company’s stock after buying an additional 402 shares during the period. Stephens Consulting LLC’s holdings in AstraZeneca were worth $78,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in AZN. Banque Transatlantique SA acquired a new position in AstraZeneca during the fourth quarter worth $26,000. Confluence Investment Management LLC acquired a new position in AstraZeneca during the first quarter worth $27,000. Mascagni Wealth Management Inc. acquired a new position in AstraZeneca during the fourth quarter worth $29,000. FNY Investment Advisers LLC acquired a new position in shares of AstraZeneca in the first quarter valued at $29,000. Finally, Highline Wealth Partners LLC increased its holdings in shares of AstraZeneca by 447.4% in the first quarter. Highline Wealth Partners LLC now owns 416 shares of the company’s stock valued at $31,000 after purchasing an additional 340 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

AstraZeneca Price Performance

NASDAQ:AZN opened at $73.55 on Tuesday. AstraZeneca PLC has a one year low of $61.24 and a one year high of $87.68. The company has a market cap of $228.10 billion, a P/E ratio of 32.54, a P/E/G ratio of 1.42 and a beta of 0.38. The firm’s fifty day moving average price is $69.98 and its two-hundred day moving average price is $70.35. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.93 and a quick ratio of 0.74.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings results on Tuesday, April 29th. The company reported $1.24 EPS for the quarter, beating the consensus estimate of $1.10 by $0.14. AstraZeneca had a net margin of 13.01% and a return on equity of 32.23%. The business had revenue of $13.59 billion for the quarter, compared to the consensus estimate of $13.71 billion. During the same period in the prior year, the company posted $2.06 earnings per share. AstraZeneca’s revenue was up 7.2% compared to the same quarter last year. Equities analysts expect that AstraZeneca PLC will post 4.51 earnings per share for the current year.

Analyst Ratings Changes

Separately, BNP Paribas initiated coverage on shares of AstraZeneca in a report on Tuesday, April 15th. They issued an “outperform” rating and a $75.00 price objective on the stock. One research analyst has rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $85.00.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.